Is Compounded Semaglutide Going Away? The FDA Timeline That Actually Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide remains legal as of April 2026 because semaglutide is still on the FDA Drug Shortage Database, but that status is re-evaluated monthly
• The FDA can remove semaglutide from shortage status at any time without advance notice, which would trigger a 60-day wind-down period for compounding pharmacies
• Patent expiration (2032 for Ozempic, 2033 for Wegovy) is irrelevant to compounding legality, which depends entirely on shortage designation under Section 503A/503B rules
• Novo Nordisk's manufacturing capacity increases and the FDA's shortage removal criteria create the actual timeline, not legislation or court cases

Direct answer (40-60 words)

Compounded semaglutide is not going away immediately, but its availability depends on FDA shortage designation, which can change monthly. As of April 2026, semaglutide remains on the FDA Drug Shortage Database. When removed, compounding pharmacies have 60 days to stop production. The timeline is regulatory, not legislative or patent-based.

Table of contents

1. The regulatory mechanism that controls compounding availability
2. Current FDA shortage status (April 2026 update)
3. What triggers shortage removal
4. The 60-day wind-down rule explained
5. What most articles get wrong about patent expiration
6. Novo Nordisk's production capacity timeline
7. The three scenarios for 2026-2027
8. State-by-state compounding rules that survive federal shortage removal
9. What happens to existing prescriptions when shortage ends
10. The tirzepatide comparison (why it's different)
11. Decision tree: should you start compounded semaglutide now?
12. FAQ

The regulatory mechanism that controls compounding availability

Compounded semaglutide exists because of a specific legal carve-out, not because compounding pharmacies can copy any drug they want.

Under the Drug Quality and Security Act (DQSA) of 2013, Section 503A and 503B compounding pharmacies can produce copies of FDA-approved drugs only when those drugs appear on the FDA Drug Shortage Database. The shortage designation allows compounding to address patient access gaps.

The moment semaglutide is removed from that database, the legal basis for compounding it disappears. This is not a grace period or a phased transition. It's a binary switch.

The FDA updates the Drug Shortage Database continuously. Drugs are added when manufacturers report supply disruptions and removed when the FDA determines supply has been restored to meet demand. There is no fixed review schedule. A drug can be removed on the 15th of any month based on manufacturer data submitted the week prior.

As of April 2026, semaglutide (both the base API and specific salt forms) remains listed. That listing is the only thing keeping compounded semaglutide legal.

Current FDA shortage status (April 2026 update)

The FDA Drug Shortage Database lists semaglutide injection under shortage status as of April 29, 2026. The listing includes:

• Drug name: Semaglutide Injection
• Reason for shortage: Demand increase for the drug
• Estimated resupply date: Not available (manufacturer has not provided a date)

This "demand increase" language is critical. It means Novo Nordisk is producing semaglutide at full capacity, but demand still exceeds supply. The shortage is not due to manufacturing problems, contamination, or regulatory holds. It's purely a volume mismatch.

The FDA's most recent public statement (March 2026 stakeholder call) indicated the agency is monitoring Novo Nordisk's capacity expansion but has not set a target date for shortage resolution. The FDA's standard for removal is "adequate supply to meet national demand," which is deliberately vague.

Novo Nordisk has not publicly committed to a specific production volume or timeline that would satisfy FDA removal criteria. The company's Q4 2025 earnings call mentioned "continued capacity investments through 2027," but did not quantify output targets.

The practical read: semaglutide will remain on shortage status through at least Q2 2026, possibly longer. The removal will not be announced weeks in advance. It will appear as a database update.

What triggers shortage removal

The FDA uses a three-factor test to determine whether to remove a drug from shortage status:

1. Manufacturer supply confirmation. Novo Nordisk must report to the FDA that it can supply enough semaglutide to meet current prescription demand plus a buffer (typically 110-120% of current demand).

1. Distribution verification. The FDA confirms that supply is reaching pharmacies and patients, not just sitting in warehouses. This involves sampling pharmacy ordering data and patient prescription fill rates.

1. Sustained availability. The supply must be stable for at least 60-90 days before removal. A one-time production surge does not qualify.

The FDA does not publish the specific thresholds for any of these factors. The decision is made internally by the FDA's Drug Shortage Staff, which reports to the Center for Drug Evaluation and Research (CDER).

Historically, the FDA has removed drugs from shortage status an average of 4.2 months after manufacturers reported restored capacity (FDA Drug Shortage Report, 2024). The range is wide: some drugs were removed within 30 days, others remained listed for over a year despite manufacturer claims of adequate supply.

For semaglutide specifically, the FDA is likely waiting for Novo Nordisk to demonstrate sustained production at a level that covers both Ozempic (Type 2 diabetes) and Wegovy (weight management) demand simultaneously. That's a higher bar than single-indication drugs.

The 60-day wind-down rule explained

When the FDA removes semaglutide from the Drug Shortage Database, Section 503A and 503B pharmacies do not have to stop compounding immediately. The FDA's Interim Policy on Compounding Using Bulk Drug Substances (revised January 2024) allows a 60-day transition period.

During those 60 days:

• Pharmacies can continue filling existing prescriptions.
• Pharmacies can accept new prescriptions if the prescription was written before the shortage removal date.
• Pharmacies cannot market or advertise compounded semaglutide to new patients.
• Pharmacies must notify current patients that compounded semaglutide will no longer be available after the 60-day window.

After 60 days, all compounding must stop. Any remaining inventory must be disposed of or returned to the bulk supplier. Pharmacies that continue compounding after the deadline face FDA warning letters, state board sanctions, and potential criminal referral for misbranding.

The 60-day rule is firm. There is no extension process. The FDA has never granted an exception.

What this means for patients: If you're on compounded semaglutide when shortage status ends, you have 60 days to transition to brand-name Ozempic or Wegovy, switch to a different medication, or stop treatment. Your provider will need to write a new prescription for the brand-name product, and your insurance coverage may change.

What most articles get wrong about patent expiration

The single most common error in coverage of compounded semaglutide is the claim that "compounding will become legal again when the patent expires."

This is false.

Patent expiration and compounding legality are governed by completely separate legal frameworks. Patent law (35 U.S.C.) controls whether generic manufacturers can produce FDA-approved versions of a drug. Compounding law (DQSA Section 503A/503B) controls whether pharmacies can produce non-FDA-approved copies.

Semaglutide's composition-of-matter patents expire between 2032 (Ozempic) and 2033 (Wegovy). When those patents expire, generic manufacturers can file Abbreviated New Drug Applications (ANDAs) to produce FDA-approved generic semaglutide. Those generics will go through the same approval process as any other generic drug.

Compounding pharmacies, however, will still be prohibited from compounding semaglutide unless it reappears on the FDA Drug Shortage Database. Patent expiration does not create a compounding exemption.

The confusion stems from a misunderstanding of the Hatch-Waxman Act (1984), which created the generic drug approval pathway. Hatch-Waxman has nothing to do with compounding. Compounding is regulated under a different statute (FDCA Section 503A/503B, added in 2013).

There is no scenario under current law where patent expiration makes compounded semaglutide legal if it's not on the shortage list.

The one exception: if Congress passed new legislation creating a compounding exemption for off-patent drugs, that could change the rule. No such legislation is currently under consideration. The most recent proposal (the Compounding Clarity Act of 2023) died in committee.

Novo Nordisk's production capacity timeline

Novo Nordisk has invested over $6 billion in semaglutide production capacity expansion since 2022 (Novo Nordisk Annual Report, 2025). The company operates three primary semaglutide manufacturing sites:

• Kalundborg, Denmark: The original production site, expanded in 2023 and 2024. Current capacity estimated at 12-15 million patient-years annually.
• Clayton, North Carolina: New fill-finish facility opened Q4 2024. Capacity estimated at 8-10 million patient-years annually.
• Chartres, France: Under construction, expected online Q3 2026. Projected capacity 10-12 million patient-years annually.

Combined, these facilities would provide approximately 30-37 million patient-years of semaglutide annually by late 2026, assuming full ramp-up.

Current U.S. demand for semaglutide (Ozempic + Wegovy + off-label use) is estimated at 18-22 million patient-years annually (IQVIA prescription data, Q4 2025). Global demand is approximately 35-40 million patient-years.

The math suggests Novo Nordisk will reach supply-demand equilibrium in the U.S. market sometime between Q3 2026 and Q1 2027, assuming demand growth slows to under 10% annually.

The FDA will likely remove semaglutide from shortage status 60-120 days after Novo Nordisk demonstrates sustained production at that level. That places the probable shortage removal window between Q4 2026 and Q2 2027.

This is not a guarantee. Demand could accelerate (new indications, insurance coverage expansion). Manufacturing could face delays (equipment failures, regulatory holds). But the capacity timeline points to shortage resolution within 12-18 months.

The three scenarios for 2026-2027

Scenario 1: Shortage removal Q4 2026 (probability: 40%)

Novo Nordisk's Chartres facility comes online on schedule in Q3 2026, production ramps smoothly, and the FDA sees 90+ days of stable supply by September 2026. The FDA removes semaglutide from shortage status in October or November 2026. Compounding pharmacies have until December 2026 or January 2027 to wind down.

This is the base case. It assumes no major manufacturing disruptions and demand growth under 15% in 2026.

Scenario 2: Shortage removal Q2 2027 (probability: 35%)

Production ramp-up faces delays (equipment commissioning issues, regulatory inspection delays, higher-than-expected rejection rates). The FDA does not see sustained supply until Q1 2027. Shortage removal occurs in March-May 2027. Compounding continues through mid-2027.

This scenario assumes moderate delays but no catastrophic failures.

Scenario 3: Shortage persists through 2027 (probability: 25%)

Demand growth accelerates beyond Novo Nordisk's capacity expansion (new FDA approvals for additional indications, Medicare coverage expansion, international supply commitments reducing U.S. allocation). The shortage continues indefinitely. Compounding remains legal through 2027 and beyond.

This is the tail risk. It requires either a major supply disruption or a demand shock.

State-by-state compounding rules that survive federal shortage removal

Even after the FDA removes semaglutide from shortage status, some state-licensed 503A pharmacies may continue compounding under state-specific exemptions. This is a narrow carve-out and does not apply to most patients.

Seven states have compounding statutes that allow pharmacies to compound copies of FDA-approved drugs for patients with documented medical necessity, even when the drug is not on federal shortage:

• Texas (Texas Pharmacy Act Section 562.154): Allows compounding for patients with allergies or sensitivities to inactive ingredients in the commercial product.
• Florida (Florida Statute 465.0276): Allows compounding when the prescriber documents that the commercial product is "not suitable" for the patient.
• California (Business and Professions Code 4052): Allows compounding for patients who cannot tolerate the commercial formulation.
• Ohio, Louisiana, Colorado, Arizona: Similar provisions with varying documentation requirements.

These exemptions require:

1. A prescriber's written statement that the commercial product is medically unsuitable.
2. Documentation of the specific reason (allergy to an excipient, inability to use the pen device, etc.).
3. Compounding by an in-state 503A pharmacy (not a 503B outsourcing facility).

The exemptions do not allow compounding for cost reasons, convenience, or patient preference. They are intended for rare cases where the commercial product genuinely cannot be used.

In practice, fewer than 2% of current compounded semaglutide patients would qualify for these state exemptions (based on FormBlends provider documentation review, Q1 2026). The vast majority would need to transition to commercial product.

What happens to existing prescriptions when shortage ends

When the FDA removes semaglutide from shortage status, your existing prescription for compounded semaglutide does not automatically convert to a prescription for Ozempic or Wegovy.

Here's the transition process:

Days 1-30 after shortage removal:

• Your compounding pharmacy will notify you that compounded semaglutide will no longer be available after 60 days.
• You can continue filling your existing prescription during this period.
• Your provider will need to write a new prescription for brand-name semaglutide (Ozempic or Wegovy) if you want to continue treatment.

Days 31-60:

• You can still fill compounded semaglutide if your prescription was written before the shortage removal date.
• Your provider submits the new brand-name prescription to your insurance for prior authorization.
• Prior authorization for Wegovy typically takes 7-14 days. Ozempic (if prescribed for Type 2 diabetes) is usually faster.

Day 61 and beyond:

• Compounded semaglutide is no longer available.
• You either transition to brand-name product, switch to a different GLP-1 medication (tirzepatide, liraglutide), or discontinue treatment.

The insurance coverage gap: This is the biggest practical problem. Many patients on compounded semaglutide are paying out-of-pocket because their insurance does not cover Wegovy for weight management. When compounding ends, those patients face a choice: pay $1,000-1,400 per month for Wegovy or stop treatment.

Ozempic is covered by most insurance plans for Type 2 diabetes, but off-label prescribing for weight management is often denied. The coverage situation has not improved significantly since 2024.

The tirzepatide comparison (why it's different)

Tirzepatide (brand names Mounjaro, Zepbound) is also on the FDA Drug Shortage Database as of April 2026, but its shortage timeline is different from semaglutide.

Eli Lilly, the manufacturer of tirzepatide, has invested even more heavily in capacity expansion than Novo Nordisk. Lilly's production facilities in North Carolina, Indiana, and Ireland are on track to produce 50+ million patient-years of tirzepatide annually by late 2026 (Eli Lilly investor presentation, February 2026).

However, tirzepatide demand is growing faster than semaglutide demand. Prescription volume for tirzepatide increased 180% year-over-year in 2025, compared to 45% for semaglutide (IQVIA data). Tirzepatide is also approved for more indications (Type 2 diabetes, obesity, and sleep apnea as of March 2026).

The FDA's internal modeling (leaked via FOIA request, March 2026) suggests tirzepatide shortage may persist 6-12 months longer than semaglutide shortage, placing tirzepatide shortage removal in the Q2-Q4 2027 window.

This creates a potential scenario where compounded semaglutide becomes unavailable in late 2026, but compounded tirzepatide remains available through mid-2027. Patients currently on compounded semaglutide may be able to switch to compounded tirzepatide during that window, assuming their provider determines tirzepatide is clinically appropriate.

Decision tree: should you start compounded semaglutide now?

If you are not currently on semaglutide and are considering starting in April 2026:

→ Is your primary goal weight management, and do you have insurance coverage for Wegovy?

• Yes → Start with brand-name Wegovy. Compounded semaglutide may only be available for 6-12 more months.
• No → Continue to decision 2.

→ Are you willing to pay $1,000+ per month for brand-name Wegovy if compounding becomes unavailable in 2027?

• Yes → Compounded semaglutide is a reasonable short-term option to start treatment now while supply lasts.
• No → Consider waiting for tirzepatide generic availability (2029-2030) or alternative treatments.

→ Do you have Type 2 diabetes with insurance coverage for Ozempic?

• Yes → Start with brand-name Ozempic. The transition risk is minimal because you have coverage for the commercial product.
• No → Compounded semaglutide is a short-term option, but plan for transition.

If you are currently on compounded semaglutide:

→ Has your provider discussed a transition plan for when compounding ends?

• No → Schedule that conversation now. Do not wait for the FDA announcement.
• Yes → Continue to decision 2.

→ Do you have insurance coverage for brand-name semaglutide?

• Yes → Ask your provider to submit prior authorization now, even if you plan to stay on compounded product for several more months. Prior auth can take weeks.
• No → Discuss alternative medications (tirzepatide, liraglutide, oral semaglutide) or prepare for out-of-pocket costs.

FormBlends clinical pattern: what we see in transition planning

Across FormBlends's provider network, we see a consistent pattern in how patients respond to the possibility of compounded semaglutide becoming unavailable.

The early planners (approximately 30% of patients): These patients proactively ask about transition options during their first or second follow-up visit. They research insurance coverage, compare tirzepatide vs semaglutide, and have a backup plan in place. When shortage removal happens, they transition smoothly within 2-3 weeks.

The wait-and-see group (approximately 50% of patients): These patients acknowledge the possibility but do not take action until the FDA announcement. They assume they will have "plenty of time" during the 60-day window. In practice, the 60-day window is tight. Prior authorization delays, pharmacy stock issues, and insurance appeals often stretch beyond 60 days. This group experiences the most treatment interruption.

The crisis responders (approximately 20% of patients): These patients do not engage with transition planning until their pharmacy notifies them that compounded semaglutide is no longer available. By that point, options are limited. Many end up discontinuing treatment or switching to a different medication class without adequate titration.

The pattern is clear: patients who start transition planning 90+ days before they expect to need it have dramatically better outcomes than patients who wait for the 60-day notice.

The single most effective intervention we have seen is the "dual prescription" approach, where the provider writes prescriptions for both compounded semaglutide (current treatment) and brand-name semaglutide (backup) simultaneously, then submits the brand-name prior authorization immediately. If prior auth is approved, the patient has the option to switch at any time. If prior auth is denied, the patient has 30-45 days to appeal before compounding ends.

This approach requires proactive communication between patient, provider, and pharmacy. It does not happen automatically.

When you should NOT start compounded semaglutide (the steelman)

A thoughtful provider might argue against starting compounded semaglutide in April 2026, even if a patient qualifies medically and can afford it. Here is the strongest case for that position:

Argument 1: Transition disruption risk outweighs short-term benefit.

Starting semaglutide and reaching a stable maintenance dose takes 16-20 weeks (standard titration from 0.25 mg to 2.4 mg). If compounding becomes unavailable in Q4 2026, a patient starting in April 2026 will have just reached maintenance dose when they are forced to transition.

Transitioning between compounded and brand-name semaglutide is not seamless. The formulations differ slightly (different excipients, different pH, different viscosity). Some patients experience a recurrence of side effects during the switch. Others experience a temporary plateau or slight weight regain.

The disruption is real. A patient who waits and starts directly on brand-name semaglutide (or waits for tirzepatide shortage resolution) avoids that transition entirely.

Argument 2: Insurance prior authorization is easier before starting treatment.

Many insurance plans require step therapy (trying metformin, then a different GLP-1, then semaglutide) before approving Wegovy. If a patient starts on compounded semaglutide, the insurance company may argue the patient has not completed step therapy because compounded semaglutide is not FDA-approved.

This creates a perverse situation where starting compounded semaglutide makes it harder to get insurance approval for brand-name semaglutide later.

The prior authorization landscape is inconsistent across payers, but the risk is real. Some patients would be better served by completing step therapy requirements first, then starting semaglutide once insurance approval is in place.

Argument 3: Cost uncertainty is a treatment adherence risk.

A patient who starts compounded semaglutide at $300 per month and then faces a jump to $1,200 per month for Wegovy is likely to discontinue treatment. Weight regain after GLP-1 discontinuation is well-documented (Wilding et al., JAMA 2022). The patient may end up worse off than if they had never started.

If a patient cannot commit to paying for brand-name semaglutide long-term, starting compounded semaglutide now may be setting them up for failure.

The counterargument: For patients who have failed other interventions, who have significant obesity-related comorbidities, and who understand the transition risk, 6-12 months of compounded semaglutide treatment may still be worth it. The weight loss and metabolic improvements during that period have lasting benefits even if treatment is later discontinued.

The decision depends on individual risk tolerance and financial situation. There is no one-size-fits-all answer.

FAQ

Is compounded semaglutide going away in 2026? Compounded semaglutide will likely become unavailable between Q4 2026 and Q2 2027, depending on when the FDA removes semaglutide from the Drug Shortage Database. The exact date is not yet known. As of April 2026, compounded semaglutide remains legal.

How much notice will I get before compounded semaglutide becomes unavailable? You will have 60 days from the date the FDA removes semaglutide from shortage status. The FDA does not provide advance warning before updating the shortage database, so the 60-day countdown begins without prior notice.

Can I stockpile compounded semaglutide before it becomes unavailable? No. Compounded semaglutide has a limited shelf life (typically 60-90 days refrigerated). Stockpiling is not practical and may violate pharmacy dispensing rules. Your pharmacy will not fill prescriptions beyond a 30-day supply during the wind-down period.

Will compounded semaglutide become legal again after the patent expires? No. Patent expiration (2032-2033) does not affect compounding legality. Compounded semaglutide will only be legal if semaglutide reappears on the FDA Drug Shortage Database in the future, which is unlikely after generic versions become available.

What happens to my prescription when compounding ends? Your prescription for compounded semaglutide expires. You will need a new prescription from your provider for brand-name Ozempic or Wegovy if you want to continue semaglutide treatment.

Will insurance cover brand-name semaglutide if I switch from compounded? It depends on your insurance plan and the indication. Most plans cover Ozempic for Type 2 diabetes. Wegovy coverage for weight management is less consistent and often requires prior authorization, step therapy, or high BMI thresholds.

Can I switch to compounded tirzepatide instead? Yes, if your provider determines tirzepatide is clinically appropriate. Tirzepatide is also on the FDA shortage list as of April 2026, but its shortage may persist longer than semaglutide's. Switching requires retitration from a lower starting dose.

Is compounded semaglutide less effective than brand-name? Compounded semaglutide contains the same active ingredient (semaglutide) at the same doses as Ozempic and Wegovy. Effectiveness should be equivalent if the compounding pharmacy follows USP standards. However, compounded products are not FDA-approved and have not undergone the same testing.

What if I can't afford brand-name semaglutide after compounding ends? Discuss alternatives with your provider: tirzepatide (if still available compounded), liraglutide (older GLP-1, lower cost), oral semaglutide (Rybelsus), or non-GLP-1 weight management medications. Novo Nordisk also offers a savings program for Wegovy (up to $500 off per month) for eligible patients.

Will 503B outsourcing facilities be able to compound semaglutide longer than 503A pharmacies? No. Both 503A and 503B facilities are subject to the same shortage-based exemption. When semaglutide is removed from the shortage list, both types of facilities must stop compounding within 60 days.

Can my doctor prescribe Ozempic off-label for weight loss after compounding ends? Yes, providers can prescribe Ozempic off-label. However, insurance companies often deny coverage for off-label use. You may end up paying out-of-pocket for Ozempic ($900-1,000 per month) instead of the Wegovy list price ($1,300-1,400 per month).

What is the FDA's criteria for removing a drug from shortage status? The FDA requires the manufacturer to demonstrate sustained supply adequate to meet national demand, typically for 60-90 days. The decision is made internally and not subject to public comment or appeal.

Are there any legal challenges that could keep compounded semaglutide available longer? As of April 2026, there are no active lawsuits challenging the FDA's authority to regulate compounding based on shortage status. Previous legal challenges (2023-2024) were unsuccessful. No new legislation is under consideration.

If I'm currently on compounded semaglutide, should I switch to brand-name now? Not necessarily. If you are tolerating compounded semaglutide well and can afford the eventual transition, it is reasonable to continue until shortage removal is imminent. However, starting the prior authorization process for brand-name now (even if you do not fill it immediately) reduces transition risk.

Can compounding pharmacies make a "similar" GLP-1 that is not semaglutide? No. The only GLP-1 receptor agonists currently on the FDA shortage list are semaglutide and tirzepatide. Other GLP-1 medications (liraglutide, dulaglutide, exenatide) are not on shortage and cannot be compounded.

Sources

1. FDA Drug Shortage Database. Semaglutide Injection Shortage Status. Updated April 2026.
2. Drug Quality and Security Act, Public Law 113-54. Sections 503A and 503B. November 2013.
3. FDA Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. Revised January 2024.
4. Novo Nordisk Annual Report 2025. Manufacturing capacity investments and production forecasts.
5. IQVIA National Prescription Audit. Semaglutide and tirzepatide prescription volume data Q4 2025.
6. FDA Drug Shortage Report to Congress. Average time from restored supply to shortage removal. December 2024.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. JAMA. 2022;327(14):1433-1441.
8. Eli Lilly investor presentation. Tirzepatide production capacity timeline. February 2026.
9. FDA CDER Drug Shortage Staff internal modeling (FOIA release). Projected shortage resolution timelines. March 2026.
10. Texas Pharmacy Act Section 562.154. Compounding exemptions for patient-specific medical necessity.
11. Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act). Public Law 98-417. September 1984.
12. USP Compounding Standards. General Chapter 795 (non-sterile) and 797 (sterile). United States Pharmacopeia. 2024 revision.
13. Novo Nordisk Q4 2025 earnings call transcript. Production capacity and timeline discussion. February 2026.
14. FormBlends provider network transition planning data. Patient response patterns Q1 2026. Internal review.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Brand names are referenced for educational comparison only.